The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The month saw the first commissioner's priority voucher approval in oncology.
